ResMed (RMD) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
ResMed · Health Care · ref. ETF XLV · 50 calls · price $235.04
What the company does: ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.
📈 ResMed (RMD) stock price
$235.04-13.0% over range
Oct 14, 25low $182.82 · high $275.96Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 9 analysts
📊 JPI status : ResMed has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 RMD price target & analyst consensus — price $235
The price target · all analysts combined (9 targets)
Highest target · 1 firm of 9$267+13.6%
Median target · of 9 targets$230-2.1%
Lowest target · 1 firm of 9$215-8.5%
Current price$235.04
Where these 9 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
222%
$262 ↔ $267
Below
778%
$215 ↔ $235
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Wells Fargo — 61% of its targets hit on this sector (403 calls tested). It aims for $215 (-8.5 %), call made on August 8, 2026, maturing on August 8, 2027 (67 d ago).
The 2 reliable analysts
$220-6.4 %
The 7 other firms
$230-2.1 %
How to read it: the 2 reliable firms are not filtered by optimism — 0 aim above the price, 2 below, hence their $220 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 9 ratings (last 6 months)
Strong Buy00%
Buy333%
Hold667%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 RMD price target all
All 50 calls, one by one, with our verdict on each firm.
→ See all 50 targets, analyst by analyst💡 The best analysts on RMD most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in RMD? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about ResMed? The JPI assistant answers using our backtest data.
💰 ResMed dividend: yield, history & growth › open the full page
1.19%annual yield
📈 Steady dividend — 13 yrs of consecutive dividend increases
That's ~$2.40 per share per year.
📈 ResMed fundamentals: valuation, margins & growth › open the full page
P/E 22.5Net margin 26.9 %Revenue growth +8.6 %Average P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2023
marg. 21 %
2024
Rev +11%Profit +14%
2025
Rev +10%Profit +37%
2026
Rev +10%Profit +9%
🔎 Detailed analyses
✅ Historical analyst reliability on RMD
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Morgan Stanley ↗ | 100% | +47.2% | 4 |
| Goldman Sachs ↗ | 100% | +40.1% | 3 |
| Deutsche Bank ↗ | 100% | +25.1% | 4 |
| B of A Securities ↗ | 88% | +17.1% | 8 |
| Oppenheimer ↗ | 80% | +23.9% | 5 |
| RBC Capital ↗ | 73% | +4.1% | 11 |
| Needham ↗ | 70% | +16.7% | 10 |
| Credit Suisse | 67% | +8.8% | 3 |
| Keybanc ↗ | 67% | +3.1% | 12 |
| Baird ↗ | 67% | -0.4% | 3 |
📊 What $1,000 invested in ResMed would be worth › open the full page
In short — $1,000 invested in ResMed 10 years ago would be worth $3,630 today, i.e. +14%/yr on average. Best year: 2020 (+37%), worst: 2022 (-20%). Price performance, excluding dividends.
If I'd invested $1,000 in ResMed
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $852 | -15% |
| 3 years ago | $936 | -6% |
| 5 years ago | $917 | -8% |
Return by year (ResMed)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -19% | $809 (-19%) |
| 2025 | +5% | $852 (-15%) |
| 2024 | +33% | $1,133 (+13%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on ResMed
Loading news…
📋 All analyst calls on RMD
Filtered on — · ✕ show all
RBC Capital ↗
Sep 15, 26
▲ Outperform · 🎯$262
Price at call : $228.25 — upside +15%
Today : $235.04 — upside +11%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Sep 15, 27
matures : Sep 15, 27
▲ Overweight · 🎯$267
Price at call : $240.1 — upside +11%
Today : $235.04 — upside +14%
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Aug 31, 27
matures : Aug 31, 27
Rothschild & Co
Aug 19, 26
■ Neutral neutral · not a buy · 🎯$230
Price at call : $228.44 — gap to target +1%
Today : $235.04 — gap to target -2%
🎯 on RMD : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Aug 19, 27
matures : Aug 19, 27
RBC Capital ↗
Aug 7, 26
■ Sector Perform neutral · not a buy · 🎯$244
Price at call : $220.05 — gap to target +11%
Today : $235.04 — gap to target +4%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
Piper Sandler ↗
Aug 7, 26
■ Neutral neutral · not a buy · 🎯$225
Price at call : $220.05 — gap to target +2%
Today : $235.04 — gap to target -4%
🎯 on RMD : no call matured yet · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
▲ Overweight · 🎯$255
Price at call : $220.05 — upside +16%
Today : $235.04 — upside +8%
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
Wells Fargo ↗
Aug 7, 26
■ Equal-Weight neutral · not a buy · 🎯$215
Price at call : $220.05 — gap to target -2%
Today : $235.04 — gap to target -9%
🎯 on RMD : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
▲ Outperform · 🎯$220
Price at call : $202.76 — upside +9%
Today : $235.04 — upside -6%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Jul 15, 27
matures : Jul 15, 27
See the other 42 calls, newest to oldest
■ Neutral neutral · not a buy · 🎯$235
Price at call : $198.5 — gap to target +18%
Today : $235.04 — gap to target -0%
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
■ Hold neutral · not a buy · 🎯$225
Price at call : $198.5 — gap to target +13%
Today : $235.04 — gap to target -4%
🎯 on RMD : no call matured yet · 📊 on Health : 51.2% · +4.7% (383 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
RBC Capital ↗
Jul 8, 26
▲ Outperform · 🎯$276
Price at call : $208.45 — upside +32%
Today : $235.04 — upside +17%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Wells Fargo ↗
Jul 8, 26
■ Equal-Weight neutral · not a buy · 🎯$225
Price at call : $205.84 — gap to target +9%
Today : $235.04 — gap to target -4%
🎯 on RMD : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
▲ Overweight · 🎯$266
Price at call : $188.45 — upside +41%
Today : $235.04 — upside +13%
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Jun 22, 27
matures : Jun 22, 27
Morgan Stanley ↗
Jun 17, 26
■ Equal-Weight neutral · not a buy · 🎯$230
Price at call : $186.29 — gap to target +23%
Today : $235.04 — gap to target -2%
🎯 on RMD : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Jun 17, 27
matures : Jun 17, 27
▲ Buy · 🎯$270
Price at call : $193.94 — upside +39%
Today : $235.04 — upside +15%
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Jun 15, 27
matures : Jun 15, 27
RBC Capital ↗
May 1, 26
▲ Outperform · 🎯$321
Price at call : $209.43 — upside +53%
Today : $235.04 — upside +37%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
Wells Fargo ↗
May 1, 26
■ Equal-Weight neutral · not a buy · 🎯$227
Price at call : $209.43 — gap to target +8%
Today : $235.04 — gap to target -3%
🎯 on RMD : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
▲ Overweight · 🎯$290
Price at call : $217.14 — upside +34%
Today : $235.04 — upside +23%
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Apr 27, 27
matures : Apr 27, 27
▲ Buy · 🎯$340
Price at call : $228.87 — upside +49%
Today : $235.04 — upside +45%
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Apr 9, 27
matures : Apr 9, 27
▲ Buy · 🎯$345
Price at call : $251.41 — upside +37%
Today : $235.04 — upside +47%
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Feb 2, 27
matures : Feb 2, 27
RBC Capital ↗
Jan 30, 26
▲ Outperform · 🎯$314
Price at call : $254.74 — upside +23%
Today : $235.04 — upside +34%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Jan 30, 27
matures : Jan 30, 27
Piper Sandler ↗
Jan 30, 26
■ Neutral neutral · not a buy · 🎯$275
Price at call : $254.74 — gap to target +8%
Today : $235.04 — gap to target +17%
🎯 on RMD : no call matured yet · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Jan 30, 27
matures : Jan 30, 27
Wells Fargo ↗
Jan 30, 26
■ Equal-Weight neutral · not a buy · 🎯$270
Price at call : $254.74 — gap to target +6%
Today : $235.04 — gap to target +15%
🎯 on RMD : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Jan 30, 27
matures : Jan 30, 27
■ Hold neutral · not a buy · 🎯$265
Price at call : $254.74 — gap to target +4%
Today : $235.04 — gap to target +13%
🎯 on RMD : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Jan 30, 27
matures : Jan 30, 27
■ Hold neutral · not a buy · 🎯$260
Price at call : $242.55 — gap to target +7%
Today : $235.04 — gap to target +11%
🎯 on RMD : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Dec 18, 26
matures : Dec 18, 26
■ Neutral neutral · not a buy · 🎯$275
Price at call : $247.34 — gap to target +11%
Today : $235.04 — gap to target +17%
🎯 on RMD : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Dec 16, 26
matures : Dec 16, 26
▲ Outperform · 🎯$300
Price at call : $248.95 — upside +21%
Today : $235.04 — upside +28%
🎯 on RMD : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Nov 3, 26
matures : Nov 3, 26
RBC Capital ↗
Oct 31, 25
▲ Outperform · 🎯$303
Price at call : $248.95 — upside +22%
Today : $235.04 — upside +29%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
▲ Overweight · 🎯$299
Price at call : $246.88 — upside +21%
Today : $235.04 — upside +27%
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
▲ Outperform · 🎯$300
Price at call : $246.88 — upside +22%
Today : $235.04 — upside +28%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
Morgan Stanley ↗
Oct 21, 25
▲ Overweight · 🎯$304
Price at call : $268.22 — upside +13%
Today : $235.04 — upside +29%
🎯 on RMD : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
Wells Fargo ↗
Oct 13, 25
■ Equal-Weight neutral · not a buy · 🎯$280
Price at call : $273.01 — gap to target +3%
Today : $235.04 — gap to target +19%
🎯 on RMD : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Oct 13, 26
matures : Oct 13, 26
▲ Buy · 🎯$330
Price at call : $273.29 — upside +21%
Today : $235.04 — upside +40%
Expected +21% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.1% · +2.4% (516 calls)
-17.7%
stock -18% · XLV +22%
matured Sep 18, 26
▲ Outperform · 🎯$290
Price at call : $291.44 — upside -0%
Today : $235.04 — upside +23%
Expected -0% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
-26.2%
stock -26% · XLV +22%
matured Aug 1, 26
■ Hold neutral · not a buy · 🎯$270
Price at call : $291.44 — gap to target -7%
Today : $235.04 — gap to target +15%
🎯 on RMD : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Aug 1, 26
matures : Aug 1, 26
RBC Capital ↗
Aug 1, 25
▲ Outperform · 🎯$300
Price at call : $291.44 — upside +3%
Today : $235.04 — upside +28%
Expected +3% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
-26.2%
stock -26% · XLV +22%
matured Aug 1, 26
▲ Buy · 🎯$325
Price at call : $291.44 — upside +12%
Today : $235.04 — upside +38%
Expected +12% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
-26.2%
stock -26% · XLV +22%
matured Aug 1, 26
▲ Overweight · 🎯$298
Price at call : $279.2 — upside +7%
Today : $235.04 — upside +27%
Expected +7% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
-22.9%
stock -23% · XLV +24%
matured Aug 1, 26
Piper Sandler ↗
Aug 1, 25
■ Neutral neutral · not a buy · 🎯$270
Price at call : $279.2 — gap to target -3%
Today : $235.04 — gap to target +15%
🎯 on RMD : no call matured yet · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Aug 1, 26
matures : Aug 1, 26
RBC Capital ↗
Jul 16, 25
▲ Outperform · 🎯$294
Price at call : $256.42 — upside +15%
Today : $235.04 — upside +25%
Expected +15% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
-22.4%
stock -22% · XLV +21%
matured Jul 16, 26
▲ Outperform · 🎯$270
Price at call : $254.25 — upside +6%
Today : $235.04 — upside +15%
Expected +6% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
-20.3%
stock -20% · XLV +21%
matured Jul 16, 26
RBC Capital ↗
Apr 24, 25
■ Sector Perform neutral · not a buy · 🎯$255
Price at call : $235.88 — gap to target +8%
Today : $235.04 — gap to target +8%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Apr 24, 26
matures : Apr 24, 26
▲ Buy · 🎯$285
Price at call : $235.88 — upside +21%
Today : $235.04 — upside +21%
Expected +21% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
-5.9%
stock -6% · XLV +4%
matured Apr 24, 26
▲ Overweight · 🎯$290
Price at call : $235.88 — upside +23%
Today : $235.04 — upside +23%
Expected +23% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.8% · +5.2% (364 calls)
-5.9%
stock -6% · XLV +4%
matured Apr 24, 26
Piper Sandler ↗
Apr 24, 25
■ Neutral neutral · not a buy · 🎯$248
Price at call : $235.88 — gap to target +5%
Today : $235.04 — gap to target +6%
🎯 on RMD : no call matured yet · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Apr 24, 26
matures : Apr 24, 26
▲ Overweight · 🎯$274
Price at call : $235.88 — upside +16%
Today : $235.04 — upside +17%
Expected +16% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
-5.9%
stock -6% · XLV +4%
matured Apr 24, 26
▲ Overweight · 🎯$269
Price at call : $214.08 — upside +26%
Today : $235.04 — upside +14%
Expected +26% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 33% (3 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
+3.7%
stock +4% · XLV +8%
matured Apr 21, 26
▲ Buy
Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.1% · +2.4% (516 calls)
+12.4%
stock +12% · XLV +2%
matured Mar 5, 26
■ Hold neutral · not a buy · 🎯$240
Price at call : $225.03 — gap to target +7%
Today : $235.04 — gap to target +2%
🎯 on RMD : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Mar 5, 26
matures : Mar 5, 26
Frequently asked questions
Should I buy ResMed stock?
This isn't buy advice. For ResMed, the analyst consensus is "Hold", with an average price target of $230 (-2% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on ResMed). We show the numbers — you decide.
Is it too late to buy ResMed? How high can it go?
The most bullish analyst target on ResMed is $267 (+14% above today's price); the average is $230. That's the upside they see. Check how reliable those analysts have actually been on ResMed on our site before trusting it.
Is ResMed still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 18 analysts have a real record on ResMed, the best hitting 100% over 4 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in ResMed? The case for and against
The arguments for and against, one by one, from the numbers: why invest in RMD (and why hesitate).
What has ResMed's past performance been?
Historical returns and a "how much if I had invested" calculator: RMD performance & returns.
Does ResMed pay a dividend?
Yield, consistency and growth history of the dividend: RMD's dividend.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX